← Back to Analyst Consensus 
GLPG Hold
Lakefront Biotherapeutics NV
Current Price —
Implied Upside —
Analysts 16
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Feb 25, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | $33 | 55% |
| Nov 7, 2025 | RBC Capital | maintain | Sector Perform → Sector Perform | $32 | 55% |
| Oct 22, 2025 | RBC Capital | maintain | Sector Perform → Sector Perform | $28 | 55% |
| Oct 21, 2025 | Leerink Partners | upgrade | Market Perform → Outperform | $40 | 51% |
| Feb 14, 2025 | Morgan Stanley | downgrade | Equal-Weight → Underweight | $22 | 54% |
| Jan 23, 2025 | Barclays | downgrade | Equal-Weight → Underweight | $0 | 53% |
| Nov 1, 2024 | RBC Capital | maintain | Sector Perform → Sector Perform | $30 | 55% |
| Sep 9, 2024 | Leerink Partners | initiate | — → Market Perform | $24 | 51% |
| Apr 22, 2024 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $38 | 54% |
| Apr 1, 2024 | B of A Securities | downgrade | Neutral → Underperform | $31 | 53% |
| Mar 28, 2024 | B of A Securities | downgrade | Neutral → Underperform | $31 | 53% |
| Jan 2, 2024 | B of A Securities | maintain | Neutral → Neutral | $44 | 53% |
| Aug 7, 2023 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $40 | 54% |
| Aug 1, 2023 | Morgan Stanley | reiterate | Equal-Weight → Equal-Weight | $42 | 54% |
| Jul 31, 2023 | Morgan Stanley | reiterate | Equal-Weight → Equal-Weight | $42 | 54% |
| Jul 24, 2023 | Morgan Stanley | reiterate | Equal-Weight → Equal-Weight | $42 | 54% |
| Jul 17, 2023 | Morgan Stanley | reiterate | Equal-Weight → Equal-Weight | $42 | 54% |
| Jun 26, 2023 | Morgan Stanley | reiterate | Equal-Weight → Equal-Weight | $42 | 54% |
| Jun 20, 2023 | Morgan Stanley | reiterate | — → Equal-Weight | $42 | 54% |
| Jun 12, 2023 | Morgan Stanley | reiterate | Equal-Weight → Equal-Weight | $42 | 54% |
| May 31, 2023 | JP Morgan | maintain | Neutral → Neutral | $45 | 54% |
| May 9, 2023 | Morgan Stanley | maintain | — → Equal-Weight | $42 | 54% |
| May 8, 2023 | RBC Capital | maintain | — → Sector Perform | $41 | 55% |
| May 8, 2023 | Raymond James | upgrade | Market Perform → Outperform | $69 | 54% |
| Feb 27, 2023 | RBC Capital | maintain | — → Sector Perform | $43 | 55% |
| Feb 27, 2023 | Morgan Stanley | maintain | — → Equal-Weight | $44 | 54% |
| Jan 23, 2023 | Jefferies | upgrade | Underperform → Hold | $47.2 | 52% |
| Nov 7, 2022 | RBC Capital | maintain | — → Sector Perform | $53 | 55% |
| Nov 7, 2022 | Morgan Stanley | maintain | — → Equal-Weight | $57 | 54% |
| Nov 7, 2022 | Raymond James | downgrade | Outperform → Market Perform | $0 | 54% |
| Oct 13, 2022 | Morgan Stanley | maintain | — → Equal-Weight | $63 | 54% |
| Sep 9, 2022 | Morgan Stanley | downgrade | Overweight → Equal-Weight | $61 | 54% |
| Aug 15, 2022 | Morgan Stanley | maintain | — → Overweight | $80 | 54% |
| Aug 8, 2022 | RBC Capital | maintain | — → Sector Perform | $55 | 55% |
| Jul 15, 2022 | Morgan Stanley | maintain | — → Overweight | $79 | 54% |
| May 9, 2022 | RBC Capital | maintain | — → Sector Perform | $62 | 55% |
| Feb 28, 2022 | Morgan Stanley | maintain | — → Overweight | $80 | 54% |
| Jan 27, 2022 | Citigroup | upgrade | Neutral → Buy | $0 | 54% |
| Jan 6, 2022 | Morgan Stanley | maintain | — → Overweight | $77 | 54% |
| Nov 8, 2021 | RBC Capital | maintain | — → Sector Perform | $65 | 55% |
| Aug 19, 2021 | Barclays | downgrade | Overweight → Equal-Weight | $0 | 53% |
| Aug 9, 2021 | RBC Capital | maintain | — → Sector Perform | $64 | 55% |
| May 10, 2021 | Morgan Stanley | maintain | — → Overweight | $118 | 54% |
| Apr 14, 2021 | Barclays | upgrade | Equal-Weight → Overweight | $0 | 53% |
| Mar 11, 2021 | Morgan Stanley | maintain | — → Overweight | $117 | 54% |
| Feb 22, 2021 | Raymond James | upgrade | Market Perform → Outperform | $100 | 54% |
| Jan 19, 2021 | Morgan Stanley | upgrade | Equal-Weight → Overweight | $129 | 54% |
| Nov 19, 2020 | Maxim Group | initiate | — → Buy | $170 | 42% |
| Oct 21, 2020 | Goldman Sachs | downgrade | Neutral → Sell | $0 | 54% |
| Oct 13, 2020 | Morgan Stanley | maintain | — → Equal-Weight | $159 | 54% |
Price Target Trend
Apr 23, 2026 Latest: $27.19 Jul 8, 2026
EPS Estimates
0q $-6.24
Lo: $-11.71 Hi: $-0.77
2 analysts +1q $-0.77
Lo: $-0.87 Hi: $-0.66
2 analysts 0y $-6.22
Lo: $-14.15 Hi: $-1.18
3 analysts +1y $-1.36
Lo: $-4.03 Hi: $0.35
4 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days